Central Nervous System Infection
Conditions
Brief summary
The investigators aim to study the population pharmacokinetics of children receiving the anti-infective drugs for treatment of infectious disease in central nervous system.
Detailed description
The investigators aim to study the population pharmacokinetics of children receiving the anti-infective drugs for treatment of infectious disease in central nervous system.In this study, the investigators will detect drug concentration in plasma by using residual blood samples of blood gas analysis and other clinical tests and employ computers for constructing population pharmacokinetic models.
Interventions
OTHERChildren with the usage of anti-infective drugs
According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
Sponsors
Beijing Children's Hospital
Wei Zhao
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
29 Days to 18 Years
Healthy volunteers
No
Inclusion criteria
* Children (29 days-18 years old) with anti-infective therapy against infectious disease in central nervous system. * Clinical symptoms: acute onset, fever (axillary temperature 38 ℃ or higher), headache, altered level of consciousness, vomiting, irritability, sleepiness, low muscle tone, seizures, before the fontanelle full or uplift, positive meningeal stimulation; * Aboratory examination: CSF appearance change, CSF routine WBC \>100 per ml, CSF routine WBC 10-100 per ml, glucose \<40mg/dl, protein \>100mg/dl), positive detection of etiology (bacterial culture, antigen detection, gram staining).
Exclusion criteria
* autoimmune encephalitis; * central nervous system infection complicated with tumor; * allergic to carbapenems or glycopeptide antibiotics; * other cases not suitable for enrollment (small sample size, incomplete clinical data, etc.).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| maximum concentration (Cmax) | up to 4 weeks | Cmax is a term used in pharmacokinetics refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and before the administration of a second dose. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| time to achieve maximum concentration (Tmax) | up to 4 weeks | Tmax is the term used in pharmacokinetics to describe the time at which the Cmax is observed. |
Countries
China
Contacts
Primary ContactZhao Wei, Ph.D
Outcome results
None listed